ATE242254T1 - Kondensierte 1,2,4-thiadiazinderivate, ihre herstellung und verwendung - Google Patents

Kondensierte 1,2,4-thiadiazinderivate, ihre herstellung und verwendung

Info

Publication number
ATE242254T1
ATE242254T1 AT99959255T AT99959255T ATE242254T1 AT E242254 T1 ATE242254 T1 AT E242254T1 AT 99959255 T AT99959255 T AT 99959255T AT 99959255 T AT99959255 T AT 99959255T AT E242254 T1 ATE242254 T1 AT E242254T1
Authority
AT
Austria
Prior art keywords
condensed
preparation
thiadiazine derivatives
compounds
thiadiazine
Prior art date
Application number
AT99959255T
Other languages
English (en)
Inventor
John Bondo Hansen
Flemming Elmelund Nielsen
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Application granted granted Critical
Publication of ATE242254T1 publication Critical patent/ATE242254T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT99959255T 1998-12-18 1999-12-15 Kondensierte 1,2,4-thiadiazinderivate, ihre herstellung und verwendung ATE242254T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199801693 1998-12-18
DKPA199900018 1999-01-11
PCT/DK1999/000702 WO2000037474A1 (en) 1998-12-18 1999-12-15 Fused 1,2,4-thiadiazine derivatives, their preparation and use

Publications (1)

Publication Number Publication Date
ATE242254T1 true ATE242254T1 (de) 2003-06-15

Family

ID=26063128

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99959255T ATE242254T1 (de) 1998-12-18 1999-12-15 Kondensierte 1,2,4-thiadiazinderivate, ihre herstellung und verwendung

Country Status (18)

Country Link
EP (2) EP1338600A1 (de)
JP (1) JP2002533347A (de)
KR (1) KR20010086126A (de)
CN (1) CN1137125C (de)
AT (1) ATE242254T1 (de)
AU (1) AU1649900A (de)
BR (1) BR9916279A (de)
CA (1) CA2353907A1 (de)
CZ (1) CZ20011831A3 (de)
DE (1) DE69908648T2 (de)
DK (1) DK1140945T3 (de)
ES (1) ES2200575T3 (de)
HU (1) HUP0104646A3 (de)
IL (1) IL143402A0 (de)
NO (1) NO20012966D0 (de)
PL (1) PL348237A1 (de)
PT (1) PT1140945E (de)
WO (1) WO2000037474A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001265840A1 (en) * 2000-06-26 2002-01-08 Novo-Nordisk A/S Use of potassium channel agonists for reducing fat food comsumption
WO2002000665A1 (en) * 2000-06-26 2002-01-03 Novo Nordisk A/S Use of potassium channel openers for the treatment of insulitis
EP1345947A1 (de) * 2000-12-21 2003-09-24 Novo Nordisk A/S Neues verfahren zur herstellung kondensierter 1,2,4thiadiazinderivate
JP4279685B2 (ja) 2001-01-19 2009-06-17 インスティテュート オブ ファーマコロジー アンド トキシコロジー アカデミー オブ ミリタリー メディカル サイエンシス ピーエルエイ カリウムチャネルの機能を調節するアミン誘導体、その調製方法及びその使用
WO2003031432A1 (en) 2001-10-12 2003-04-17 Novo Nordisk A/S Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor
AU2002365289A1 (en) * 2001-11-30 2003-06-10 Novo Nordisk A/S Use of selective potassium channel openers
WO2003045954A1 (en) * 2001-11-30 2003-06-05 Novo Nordisk A/S Use of selective potassium channel openers
PL370989A1 (en) 2001-12-21 2005-06-13 Novo Nordisk A/S Amide derivatives as gk activators
WO2003105896A1 (en) * 2002-06-14 2003-12-24 Novo Nordisk A/S Combined use of a modulator of cd3 and a beta cell resting compound
AU2003243921B2 (en) 2002-06-27 2009-05-07 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
AU2003239780A1 (en) * 2002-07-04 2004-01-23 Novo Nordisk A/S Polymorphic forms of a 4h-thieno(3,2-e)-1,2,4-thiadiazine 1,1-dioxide derivative
EP1670815A2 (de) 2003-09-30 2006-06-21 Novo Nordisk A/S Melanocortinrezeptoragonisten
EP2298337B1 (de) 2003-12-09 2017-02-22 Novo Nordisk A/S Regulierung des bevorzuchtes nahrungsaufnahmen mit verwendung von GLP-1 agonisten
BRPI0506662B8 (pt) 2004-01-06 2021-05-25 Novo Nordisk As compostos ativadores de glucoquinase
EP1758575A1 (de) 2004-06-11 2007-03-07 Novo Nordisk A/S Bekämpfung von arzneimittel-induzierter fettleibigkeit unter verwendung von glp-1-agonisten
US8263551B2 (en) 2004-11-22 2012-09-11 Novo Nordisk A/S Soluble, stable insulin-containing formulations with a protamine salt
EP1824835A1 (de) 2004-12-03 2007-08-29 Novo Nordisk A/S Heteroaromatische glucokinaseaktivatoren
US20080171695A1 (en) 2005-02-02 2008-07-17 Novo Nordisk A/S Insulin Derivatives
EP2256130B1 (de) 2005-02-02 2013-09-25 Novo Nordisk A/S Neuartige Insulinderivate
BRPI0609879A2 (pt) 2005-04-28 2010-05-11 Pfizer Ltd derivados de aminoácidos
MX2007015675A (es) 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
EP1904467B1 (de) 2005-07-14 2013-05-01 Novo Nordisk A/S Harnstoff-Glucokinase-Aktivatoren
EP1910317B1 (de) 2005-07-20 2013-07-03 Eli Lilly And Company 1-amino-verbundene verbindungen
ES2393757T3 (es) 2005-11-17 2012-12-27 Eli Lilly & Company Antagonistas de receptor de glucagón, preparación y usos terapéuticos
CN101410385B (zh) 2006-03-28 2011-08-24 高点制药有限责任公司 具有组胺h3受体活性的苯并噻唑类
CN100500672C (zh) * 2006-04-20 2009-06-17 山东大学 N1,N3-二取代噻吩并[3,2-e][2,1,3]噻二嗪-2,2,4-三酮类衍生物与应用
EP2402324A1 (de) 2006-05-29 2012-01-04 High Point Pharmaceuticals, LLC Benzodioxolylcyclopropylpiperazinylpyridazine
EP2086951B1 (de) 2006-11-15 2011-12-21 High Point Pharmaceuticals, LLC Neue für die behandlung von obesitas und diabetes geeignete 2-(2-hydroxyphenyl)benzothiadiazine
JP5226008B2 (ja) 2007-01-11 2013-07-03 ノボ・ノルデイスク・エー／エス ウレアグルコキナーゼアクチベーター
EP2539364A1 (de) 2010-02-26 2013-01-02 Novo Nordisk A/S Peptide zur behandlung von adipositas
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
EP2552951A1 (de) 2010-03-26 2013-02-06 Novo Nordisk A/S Neue glocagonanaloga
RU2013145013A (ru) 2011-03-28 2015-05-10 Ново Нордиск А/С Новые аналоги глюкагона
AU2012311484B2 (en) 2011-09-23 2017-04-13 Novo Nordisk A/S Novel glucagon analogues
WO2014093696A2 (en) 2012-12-12 2014-06-19 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
EP2986313B1 (de) 2013-04-18 2019-06-12 Novo Nordisk A/S Stabile, zeitverzögerte coagonisten des glucagon/glp-1-rezeptors
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
WO2016053828A1 (en) * 2014-10-03 2016-04-07 Merck Sharp & Dohme Corp. C5-c6-fused tricyclic iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
US20200223889A1 (en) 2017-03-15 2020-07-16 Novo Nordisk A/S Bicyclic Compounds Capable of Binding to Melanocortin 4 Receptor
WO2019219714A1 (en) 2018-05-15 2019-11-21 Novo Nordisk A/S Compounds capable of binding to melanocortin 4 receptor
WO2020053414A1 (en) 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0876379A1 (de) * 1996-01-17 1998-11-11 Novo Nordisk A/S Kondensierte 1,2,4-thiadiazin- und 1,4-thiazinderivate, deren herstellung und verwendung
RU2215004C2 (ru) * 1997-07-16 2003-10-27 Ново Нордиск А/С Конденсированное производное 1,2,4-тиадиазина, фармацевтическая композиция и способ получения лекарственного препарата

Also Published As

Publication number Publication date
CZ20011831A3 (cs) 2001-10-17
ES2200575T3 (es) 2004-03-01
CN1137125C (zh) 2004-02-04
EP1140945A1 (de) 2001-10-10
WO2000037474A1 (en) 2000-06-29
JP2002533347A (ja) 2002-10-08
CN1330655A (zh) 2002-01-09
EP1140945B1 (de) 2003-06-04
PL348237A1 (en) 2002-05-20
BR9916279A (pt) 2001-10-16
DE69908648D1 (de) 2003-07-10
PT1140945E (pt) 2003-10-31
NO20012966L (no) 2001-06-15
NO20012966D0 (no) 2001-06-15
HUP0104646A3 (en) 2004-05-28
DK1140945T3 (da) 2003-09-15
IL143402A0 (en) 2002-04-21
HUP0104646A2 (hu) 2002-04-29
DE69908648T2 (de) 2004-05-13
CA2353907A1 (en) 2000-06-29
KR20010086126A (ko) 2001-09-07
EP1338600A1 (de) 2003-08-27
AU1649900A (en) 2000-07-12

Similar Documents

Publication Publication Date Title
ATE242254T1 (de) Kondensierte 1,2,4-thiadiazinderivate, ihre herstellung und verwendung
CA2134964A1 (en) Bridged Aza-Bicyclic Derivatives as Substance P Antagonists
ATE260266T1 (de) 1,2,4-benzothiadiazin-derivate, ihre herstellung und verwendung
PT1259489E (pt) Compostos azapoliciclicos condensados con arilo.
ES2184960T3 (es) Nuevas pirimidin-4-onas-(5,6)-heteroaril condensadas 2,3 disustituidas.
ATE237585T1 (de) Substituierte 3,3-diamino-2-propennitrile, ihre herstellung und verwendung
HK1046404A1 (zh) 用作nmda受体拮抗剂的取代的吡咯烷-2，3，4-三酮-3-肟衍生物
DE59909607D1 (de) Tan-1057 derivate
DE59711704D1 (de) Neue carbonsäurederivate, ihre herstellung und verwendung
DE58905079D1 (de) Neue alpha-aminocarbonsaeure-derivate, ihre herstellung und verwendung.
DE69731458D1 (de) Pyrido-1,2,4-thiadiazine und pyrido-1-4-thiazinderivate, ihre herstellung und ihre verwendung
ATE252537T1 (de) Substituierte 2-hydroxybenzophenone, ihre herstellung, ihre verwendung als fungizide und ihre fungizide zusammensetzungen
ATE252546T1 (de) 3-(3-hydroxyphenyl)-3-amino-propionamidderivate
ATE229953T1 (de) Naphtho-imidazo(1,2-a)pyridin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems
DE69827706D1 (de) 5-(Heteroaryl)alkyl)-3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid (PBI) Derivate zur Behandlung von Störungen des zentralen Nervensystems
DE50006244D1 (en) Neue substituierte 3-phenoxy- und 3-phenylalkyloxy-2-phenyl-propylamine
DE60118994D1 (de) Verfahren zur Herstellung von kondensierten Cyclopentadienen, 1,3 disubstituierte Derivate und diese enthaltende Metallocen-artige Verbindungen
ATE239015T1 (de) N-substituierte azabicycloheptan-derivate, ihre herstellung und verwendung
ATE236159T1 (de) Neuartige bispidin-derivate, die sich zur behandlung von herzrhythmusstörungen eignen
ATE155479T1 (de) Neue cytarabin-derivate, ihre herstellung und verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1140945

Country of ref document: EP